lilly tirzepatide shortage Lilly's weight-loss drug removed from FDA's list Mounjaro will remain off shortage

In the US GLP1 for diabetes increased by 19%, whereas insulin decreased by 34%

Tirzepatide does not directly 'burn' fat in the way some marketing suggests, but it does support weight loss through dual receptor activation that reduces appetite and modulates metabolism

Patients with type 2 diabetes, treated with metformin alone or treated with metformin and a second OAD treatment that could be a sulfonylurea or a glinide or a sodium-glucose cotransporter-2 (SGLT-2) inhibitor or a dipeptidyl peptidase-4 (DPP-4) inhibitor, and who were not adequately controlled with this treatment (HbA1c range 7.5% to 10% for patients previously treated with metformin alone and 7% to 9% for patients previously treated with metformin and a second OAD treatment) entered a run-in period for 4 weeks

Conflict of Interests Statement: The authors have no known competing financial interests or personal relationships that could influence the work reported in this paper

For a closer look at our broader approach, explore the Gut Health Supplements collection